"We know from all medical interventions, stay time is not like a 100%... but I think we will see a significantly higher stay time than what we have seen so far on obesity treatment," said Lars Fruergaard Jorgensen at the JPMorgan Healthcare conference in San Francisco. The Danish drugmaker's chief executive said the effects patients see after being on Wegovy would be an incentive for them to continue, although it may be "too early to tell." Novo and U.S. drugmaker Eli Lilly currently dominate the market for new weight loss drugs that analysts have forecast could be worth $100 billion by the end of the decade.
Related Keywords
San Francisco , California , United States , Bengaluru , Karnataka , India , Denmark , Danish , Novo Nordisk , Bhanvi Satija , Khushi Mandowara , Eli Lilly , Lars Fruergaard Jorgensen , Reuters , Bill Berkrot , Medical Interventions , Injectable Drugs , Jorgensen ,
comparemela.com © 2020. All Rights Reserved.